focus -WSS

focus

author：comprehensive 2025-09-14 14:48:28 - browse：22

Adam's take main illustration — Molly Ferguson/STAT

It took Anavex Life Sciences seven months to finally acknowledge the failure of a late-stage clinical trial in Rett syndrome.

The negative study outcome was never in doubt, so the only surprise from Tuesday’s announcement was the company’s lame attempt at damage control. Anavex is a serial dissembler of clinical trial results, so I was expecting better spin. Instead, management barely tried, which tells you the real results from the Rett study must be truly awful.

Anavex shares fell 31% to $6 in early trading. The company’s only drug in clinical development, called blarcamesine, is a zero. Rett is the latest failure, following earlier study failures in Alzheimer’s disease and Parkinson’s disease. Yet even with Tuesday’s drop in share price, Anavex still carries a fully diluted market value of nearly $650 million.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： DeSantis wants to import drugs. Biden’s FDA blasted his plan

WSS

DeSantis wants to import drugs. Biden’s FDA blasted his plan

Overprescribed: High cost isn't America's only drug problem

Overprescribed: High cost isn't America's only drug problem

Medicare Advantage 2025 payments will dip, Biden administration says

California store owner shot dead in dispute over displaying Pride flag: Police

Scientific mystery highlights the blind spots in genomics databases

Wikipedia

focus

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

Four alarming medical procedures we’re glad history forgot

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Scientific mystery highlights the blind spots in genomics databases

Jerome Adams on the need for new antivirals for Covid

How to make over

How one medical school became remarkably diverse

How the first Native Hawaiian psychiatrist helped diversify medicine

hotspot

Mass General Brigham physicians react to latest merger step

People with mental disorders often marry others with same

National associations that represent hospice owe an apology

First Opinion on colorectal cancer screening: letter and response

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

As obesity drug market grows, telehealth companies court payers

focus

explore

hotspot

focus